MARKET

MRNA

MRNA

Moderna
NASDAQ

Real-time Quotes | Nasdaq Last Sale

163.15
+2.65
+1.65%
After Hours: 163.80 +0.65 +0.40% 19:59 05/07 EDT
OPEN
165.78
PREV CLOSE
160.50
HIGH
169.02
LOW
160.82
VOLUME
11.95M
TURNOVER
--
52 WEEK HIGH
189.26
52 WEEK LOW
46.13
MARKET CAP
65.29B
P/E (TTM)
-84.2195
1D
5D
1M
3M
1Y
5Y
U.S. support for IP rights waiver of COVID-19 vaccines meets resistance in EU
Prominent EU countries have reiterated the opposition to the U.S.-backed moves to waive patent protections for COVID-19 vaccines.German Chancellor Angela Merkel who previously voiced her opposition to U.S. plans highlighted
Seekingalpha · 11h ago
U.S. wants COVID vaccine patent waiver to benefit world, not boost China biotech
reuters.com · 17h ago
BRIEF-U.S. CDC Says Delivered 329,840,055 Doses Of Covid-19 Vaccine As Of May 8 Versus 327,124,625 Doses As Of May 7
reuters.com · 19h ago
U.S. administers 257.3 mln doses of COVID-19 vaccines –CDC
reuters.com · 19h ago
UPDATE 1-Thailand set to boost COVID-19 vaccinations, expects to approve Moderna shots
reuters.com · 1d ago
Moderna, Peloton, Microsoft: Stocks That Defined the Week
Here are seven major companies whose stocks moved on the week’s news.
The Wall Street Journal · 1d ago
The Tussle Over Covid Vaccine Patents Looks Overblown. Why Moderna and BioNTech Can Weather the Jolts.
Why waiving patents on Covid vaccines won’t hurt companies like Moderna, BioNTech, and Novavax.
Barrons.com · 1d ago
Britain free of coronavirus by August, outgoing vaccine task force chief says -Telegraph
reuters.com · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRNA. Analyze the recent business situations of Moderna through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MRNA stock price target is 177.42 with a high estimate of 231.00 and a low estimate of 83.00.
EPS
Institutional Holdings
Institutions: 801
Institutional Holdings: 199.76M
% Owned: 49.92%
Shares Outstanding: 400.18M
TypeInstitutionsShares
Increased
223
31.53M
New
223
6.56M
Decreased
183
41.32M
Sold Out
49
650.87K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Non-Executive Chairman/Co-Founder/Independent Director
Noubar Afeyan
President
Stephen Hoge
Chief Executive Officer/Director
Stephane Bancel
Chief Financial Officer
David Meline
Chief Human Resource Officer
Tracey Franklin
Chief Technology Officer
Juan Andres
General Counsel/Secretary
Lori Henderson
Other
Marcello Damiani
Other
Tal Zaks
Other
Ray Jordan
Other
Corinne Le Goff
Other
Jose Vega
Other
Tal Zvi Zaks
Independent Director
Stephen Berenson
Independent Director
Sandra Horning
Independent Director
Robert Langer
Independent Director
Elizabeth Nabel
Independent Director
Francois Nader
Independent Director
Paul Sagan
Independent Director
Elizabeth Tallett
No Data
About MRNA
Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.

Webull offers kinds of Moderna Inc stock information, including NASDAQ:MRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRNA stock methods without spending real money on the virtual paper trading platform.